Background Nausea and vomiting are commonly associated with medication use. Dopaminergic agonists have been associ- ated with these symptoms, but their impact in patients without Parkinson’s disease, such as those with restless legs syndrome (RLS), is not well characterized. Aims We sought to determine whether the non-ergoline dopamine agonist ropinirole is associated with nausea and vomiting in adults with RLS. Methods We conducted a systematic review using PUBMED, EMBASE, and clinical trial databases to identify placebo- controlled clinical trials of ropinirole for RLS treatment. We extracted data including dosing schedule and the proportion of patients reporting nausea and/or vomiting. We also determined hazard ratios (HR) using a random effects proportional hazard model. Results We extracted data from a pool of 13 studies. The prevalence of nausea in the ropinirole-treated RLS group (RLS-R; N = 1528) was 37.2% compared to 9.4% in the placebo-treated RLS group (RLS-P; N = 1395) (p < 0.0001). The prevalence of vomiting in the RLS-R group was 10.9% compared to 2.6% in the RLS-P group (p < 0.0001). Ropinirole use was asso- ciated with a higher risk of reporting nausea (HR 5.924 [4.410–7.959], p < 0.001) and experiencing vomiting (HR 4.628 [3.035–7.057], p < 0.0001). Nausea and vomiting represented nearly 50% of all adverse events reported. Conclusions
Digestive Diseases and Sciences – Springer Journals
Published: Jan 30, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud